CSMS 51230259PGAinformational

FDA Launching New 24/7 Drug Entry Review Pilot

Published Mar 7, 2022

Summary

FDA's OEIO announced a 90-day pilot (March 13 to June 13, 2022) to review drug entries nationally with 24/7 staffing across all ports, aiming to improve efficiency and explore receiving documentation earlier in the entry process.

Summary is machine-generated at the linking layer for discovery only. Refer to the source bulletin for authoritative guidance.

CSMS 51230259 · full bulletin